MICROBIOME THERAPEUTIC INNOVATION GROUP (EIN 824927284) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2017

Legal Domicile

Principal Officer

TOM FAGLEY

Phone

2025771370

Tax Period

2025-01-01 to 2025-12-31

MICROBIOME THERAPEUTIC INNOVATION GROUP, founded in 2017, is a small nonprofit in the Community Improvement sector that reported $375K in total revenue in fiscal year 2025. Revenue decreased 7% compared to the prior year.

Mission

TO REPRESENT AND PROMOTE THE VOICE OF THE COMMON BUSINESS INTEREST OF MICROBIOME THERAPEUTICS AND MICROBIOME-BASED PRODUCTS TO PROVIDE GUIDANCE AND RELATED POLICIES USED TO SEEK REGULATORY CLARITY ON ISSUES INCLUDING CLINICAL TRIALS DESIGNS, ENDPOINT SELECTIONS, AND EVIDENTIAL BURDENS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $374,885

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $374,885

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $357,576

Other Expenses $366,651

TOTAL EXPENSES $366,651

Year-over-Year Comparison

	2025	2024	Change
Revenue	$374,885	$404,063	-0.1%
Expenses	$366,651	$478,029	-0.2%
Net Income	$8,234	$-73,966	-1.1%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
STEPHEN CONAFAY	SECRETARY	1.00	Officer Director	$0	$0	$0
JOHAN VAN HYLCKAMA VLIEG	CHAIRMAN	1.00	Officer Director	$0	$0	$0
TOM FAGLEY	TREASURER	1.00	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$374,885	$366,651	$50,521	$8,234
2024	$404,063	$478,029	$42,287	$-73,966
2023	$558,236	$501,146	$116,253	$57,090
2022	$394,988	$543,529	$59,163	$-148,541
2021	$487,464	$437,474	$207,704	$49,990
2020	$262,500	$321,491	$157,714	$-58,991
2019	$420,001	$216,957	$216,705	$203,044

MICROBIOME THERAPEUTIC INNOVATION GROUP